Great West Life Assurance Co. Can boosted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 1.2% during the second quarter, Holdings Channel reports. The institutional investor owned 209,607 shares of the medical equipment provider’s stock after buying an additional 2,483 shares during the period. Great West Life Assurance Co. Can’s holdings in Hologic were worth $9,499,000 at the end of the most recent quarter.
Several other institutional investors have also recently bought and sold shares of HOLX. TrimTabs Asset Management LLC raised its position in Hologic by 88.8% in the first quarter. TrimTabs Asset Management LLC now owns 2,993 shares of the medical equipment provider’s stock worth $127,000 after buying an additional 1,408 shares in the last quarter. Advisor Partners LLC purchased a new position in Hologic during the first quarter worth $201,000. Miles Capital Inc. purchased a new position in Hologic during the first quarter worth $206,000. Beck Mack & Oliver LLC purchased a new position in Hologic during the second quarter worth $209,000. Finally, Stratos Wealth Partners LTD. purchased a new position in Hologic during the first quarter worth $210,000. 94.46% of the stock is owned by institutional investors and hedge funds.
Shares of Hologic, Inc. (NASDAQ:HOLX) opened at 37.39 on Friday. Hologic, Inc. has a 12-month low of $35.15 and a 12-month high of $46.80. The company has a 50-day moving average of $43.97 and a 200 day moving average of $42.90. The firm has a market capitalization of $10.49 billion, a PE ratio of 13.93 and a beta of 0.90.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, beating the consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The company had revenue of $806.10 million for the quarter, compared to the consensus estimate of $799.70 million. During the same quarter last year, the company posted $0.51 earnings per share. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. On average, analysts predict that Hologic, Inc. will post $2.01 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “Great West Life Assurance Co. Can Has $9.50 Million Position in Hologic, Inc. (NASDAQ:HOLX)” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://www.tickerreport.com/banking-finance/2801639/great-west-life-assurance-co-can-has-9-50-million-position-in-hologic-inc-nasdaqholx.html.
A number of equities research analysts recently issued reports on HOLX shares. Canaccord Genuity restated a “buy” rating and issued a $53.00 target price on shares of Hologic in a report on Tuesday, May 9th. Stifel Nicolaus boosted their target price on shares of Hologic from $45.00 to $48.00 and gave the company a “buy” rating in a report on Thursday, May 11th. BTIG Research restated a “buy” rating and issued a $47.00 target price on shares of Hologic in a report on Sunday, May 14th. Zacks Investment Research downgraded shares of Hologic from a “buy” rating to a “hold” rating in a report on Tuesday, May 23rd. Finally, Jefferies Group LLC set a $49.00 target price on shares of Hologic and gave the company a “buy” rating in a report on Sunday, May 28th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have given a buy rating to the stock. Hologic currently has a consensus rating of “Buy” and an average price target of $48.64.
In other news, Director Lawrence M. Levy sold 9,076 shares of the firm’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $42.80, for a total value of $388,452.80. Following the sale, the director now owns 43,165 shares in the company, valued at $1,847,462. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Elaine Ullian sold 6,902 shares of the firm’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total transaction of $276,908.24. Following the completion of the sale, the director now owns 23,810 shares in the company, valued at approximately $955,257.20. The disclosure for this sale can be found here. In the last quarter, insiders have sold 60,627 shares of company stock worth $2,632,911. Corporate insiders own 0.79% of the company’s stock.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.